All In Biotech

Drug Trial Radar · NCT05288543

A Study of Orally Administered IPG7236 in Healthy Adult Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Food Effect of Orally Administered IPG7236 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

63

Actual

Start

Apr 7, 2022

Primary completion

Mar 31, 2023

Study completion Nov 26, 2025

Sponsor

Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult participants.

Conditions

  • Atopic Dermatitis

Interventions

  • IPG7236- Single ascending doseDrug

    Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state

  • IPG7236- Multiple ascending doseDrug

    Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state

  • Placebo (Part A)Other

    Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of IPG7236 after ascending single oral doses through adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events v5Time frame: Up to 36 days
  2. To assess the safety and tolerability of IPG7236 after ascending multiple oral doses through adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events v5Time frame: Up to 45 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.